CYREN: A Potent Drug Target for Cancer, Neurodegenerative Disorders and Autoimmune Diseases

Target Name: CYREN

NCBI ID: G78996

CYREN

CYREN: A Potent Drug Target for Cancer, Neurodegenerative Disorders and Autoimmune Diseases

CYREN (FLJ27285) is a drug target and a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and biochemical properties make it an attractive target for drug development.

CYREN is a small molecule inhibitor of the enzyme IDH2, which is responsible for the production of mitochondrial DNA damage. Mitochondrial DNA damage is a hallmark of cancer and has been linked to the development of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

The IDH2 enzyme is a critical regulator of cell proliferation and survival, and its dysfunction has been implicated in the development and progression of many diseases. The CYREN drug targets this enzyme and inhibits its activity, which can lead to the collapse of the mitochondrial damaged DNA, leading to the death of cells, and the formation of apoptotic cells that can be detected and targeted by the immune system.

CYREN has been shown to be effective in preclinical models of cancer, neurodegenerative disorders, and autoimmune diseases. In cancer cell lines, CYREN has been shown to inhibit the growth and survival of cancer cells, and to cause apoptosis in a dose-dependent manner.

In neurodegenerative disorders, CYREN has been shown to protect against neurotoxicity and to improve the survival of dopaminergic neurons in Parkinson's disease and Huntington's disease.

In autoimmune diseases, CYREN has been shown to normalize the immune system and to protect against the development of autoimmune diseases.

CYREN's unique properties make it an attractive drug target and a potential biomarker for various diseases. Its ability to inhibit the IDH2 enzyme and its dose-dependent apoptotic effect on cancer cells make it an attractive addition to the arsenal of anti-cancer drugs.

CYREN has been shown to be safe and to have low toxicity in preclinical studies. This makes it a strong candidate for further development as a novel drug.

In conclusion, CYREN is a drug target and a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and biochemical properties make it an attractive target for drug development. Further studies are needed to confirm its effectiveness and to develop it as a safe and effective new drug.

Protein Name: Cell Cycle Regulator Of NHEJ

Functions: Cell-cycle-specific regulator of classical non-homologous end joining (NHEJ) of DNA double-strand break (DSB) repair, which can act both as an activator or inhibitor of NHEJ, depending on the cell cycle phase (PubMed:24610814, PubMed:28959974). Acts as a regulator of DNA repair pathway choice by specifically inhibiting classical NHEJ during the S and G2 phases, thereby promoting error-free repair by homologous recombination during cell cycle phases when sister chromatids are present (PubMed:28959974). Preferentially protects single-stranded overhangs at break sites by inhibiting classical NHEJ, thereby creating a local environment that favors homologous recombination (PubMed:28959974). Acts via interaction with XRCC5/Ku80 and XRCC6/Ku70 (PubMed:28959974). In contrast, acts as an activator of NHEJ during G1 phase of the cell cycle: promotes classical NHEJ in G1 phase cells via multivalent interactions that increase the affinity of DNA damage response proteins for DSB-associated chromatin. Also involved in immunoglobulin V(D)J recombination (By similarity). May also act as an indirect regulator of proteasome (By similarity)

The "CYREN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYREN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets